[
  {
    "title": "Why Eli Lilly's September Earnings Disappointed Wall Street - Barron's",
    "title_detail": {
      "type": "text/plain",
      "language": null,
      "base": "",
      "value": "Why Eli Lilly's September Earnings Disappointed Wall Street - Barron's"
    },
    "links": [
      {
        "rel": "alternate",
        "type": "text/html",
        "href": "https://www.barrons.com/articles/why-eli-lillys-september-earnings-disappointed-wall-street-51603801012"
      }
    ],
    "link": "https://www.barrons.com/articles/why-eli-lillys-september-earnings-disappointed-wall-street-51603801012",
    "id": "CBMiZ2h0dHBzOi8vd3d3LmJhcnJvbnMuY29tL2FydGljbGVzL3doeS1lbGktbGlsbHlzLXNlcHRlbWJlci1lYXJuaW5ncy1kaXNhcHBvaW50ZWQtd2FsbC1zdHJlZXQtNTE2MDM4MDEwMTLSAQA",
    "guidislink": false,
    "published": "Tue, 27 Oct 2020 13:16:00 GMT",
    "published_parsed": [
      2020,
      10,
      27,
      13,
      16,
      0,
      1,
      301,
      0
    ],
    "summary": "<a href=\"https://www.barrons.com/articles/why-eli-lillys-september-earnings-disappointed-wall-street-51603801012\" target=\"_blank\">Why Eli Lilly's September Earnings Disappointed Wall Street</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Barron's</font>",
    "summary_detail": {
      "type": "text/html",
      "language": null,
      "base": "",
      "value": "<a href=\"https://www.barrons.com/articles/why-eli-lillys-september-earnings-disappointed-wall-street-51603801012\" target=\"_blank\">Why Eli Lilly's September Earnings Disappointed Wall Street</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Barron's</font>"
    },
    "source": {
      "href": "https://www.barrons.com",
      "title": "Barron's"
    },
    "sub_articles": []
  },
  {
    "title": "Eli Lilly still confident in benefits of Covid antibody treatment despite end to hospital study - CNBC",
    "title_detail": {
      "type": "text/plain",
      "language": null,
      "base": "",
      "value": "Eli Lilly still confident in benefits of Covid antibody treatment despite end to hospital study - CNBC"
    },
    "links": [
      {
        "rel": "alternate",
        "type": "text/html",
        "href": "https://www.cnbc.com/2020/10/27/eli-lilly-ceo-dave-ricks-still-confident-in-covid-antibody-treatment-.html"
      }
    ],
    "link": "https://www.cnbc.com/2020/10/27/eli-lilly-ceo-dave-ricks-still-confident-in-covid-antibody-treatment-.html",
    "id": "52781148287878",
    "guidislink": false,
    "published": "Tue, 27 Oct 2020 13:19:00 GMT",
    "published_parsed": [
      2020,
      10,
      27,
      13,
      19,
      0,
      1,
      301,
      0
    ],
    "summary": "<ol><li><a href=\"https://www.cnbc.com/2020/10/27/eli-lilly-ceo-dave-ricks-still-confident-in-covid-antibody-treatment-.html\" target=\"_blank\">Eli Lilly still confident in benefits of Covid antibody treatment despite end to hospital study</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">CNBC</font></li><li><a href=\"https://www.insideindianabusiness.com/story/42823381/lilly-covid-antibody-trial-ends\" target=\"_blank\">Lilly COVID Antibody Trial Ends</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Inside INdiana Business</font></li><li><a href=\"https://www.theindianalawyer.com/articles/lilly-antibody-drug-fails-in-covid-19-study-for-hospitalized-patients\" target=\"_blank\">Lilly antibody drug fails in COVID-19 study for hospitalized patients</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Indiana Lawyer</font></li><li><a href=\"https://www.bloombergquint.com/coronavirus-outbreak/u-s-run-clinical-trial-of-eli-lilly-antibody-therapy-to-end\" target=\"_blank\">U.S. Trial of Lilly Antibody Therapy to End; No Safety Issue</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BloombergQuint</font></li><li><a href=\"https://www.nbcbayarea.com/news/coronavirus/lilly-antibody-drug-fails-in-study-of-hospitalized-covid-19-patients/2386756/\" target=\"_blank\">Lilly Antibody Drug Fails in Study of Hospitalized COVID-19 Patients</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">NBC Bay Area</font></li><li><strong><a href=\"https://news.google.com/stories/CAAqOQgKIjNDQklTSURvSmMzUnZjbmt0TXpZd1NoTUtFUWlHNS1DTWtZQU1FWF9CSk9GOWpsR0pLQUFQAQ?oc=5\" target=\"_blank\">View Full Coverage on Google News</a></strong></li></ol>",
    "summary_detail": {
      "type": "text/html",
      "language": null,
      "base": "",
      "value": "<ol><li><a href=\"https://www.cnbc.com/2020/10/27/eli-lilly-ceo-dave-ricks-still-confident-in-covid-antibody-treatment-.html\" target=\"_blank\">Eli Lilly still confident in benefits of Covid antibody treatment despite end to hospital study</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">CNBC</font></li><li><a href=\"https://www.insideindianabusiness.com/story/42823381/lilly-covid-antibody-trial-ends\" target=\"_blank\">Lilly COVID Antibody Trial Ends</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Inside INdiana Business</font></li><li><a href=\"https://www.theindianalawyer.com/articles/lilly-antibody-drug-fails-in-covid-19-study-for-hospitalized-patients\" target=\"_blank\">Lilly antibody drug fails in COVID-19 study for hospitalized patients</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Indiana Lawyer</font></li><li><a href=\"https://www.bloombergquint.com/coronavirus-outbreak/u-s-run-clinical-trial-of-eli-lilly-antibody-therapy-to-end\" target=\"_blank\">U.S. Trial of Lilly Antibody Therapy to End; No Safety Issue</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BloombergQuint</font></li><li><a href=\"https://www.nbcbayarea.com/news/coronavirus/lilly-antibody-drug-fails-in-study-of-hospitalized-covid-19-patients/2386756/\" target=\"_blank\">Lilly Antibody Drug Fails in Study of Hospitalized COVID-19 Patients</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">NBC Bay Area</font></li><li><strong><a href=\"https://news.google.com/stories/CAAqOQgKIjNDQklTSURvSmMzUnZjbmt0TXpZd1NoTUtFUWlHNS1DTWtZQU1FWF9CSk9GOWpsR0pLQUFQAQ?oc=5\" target=\"_blank\">View Full Coverage on Google News</a></strong></li></ol>"
    },
    "source": {
      "href": "https://www.cnbc.com",
      "title": "CNBC"
    },
    "sub_articles": [
      {
        "url": "https://www.cnbc.com/2020/10/27/eli-lilly-ceo-dave-ricks-still-confident-in-covid-antibody-treatment-.html",
        "title": "Eli Lilly still confident in benefits of Covid antibody treatment despite end to hospital study",
        "publisher": "CNBC"
      },
      {
        "url": "https://www.insideindianabusiness.com/story/42823381/lilly-covid-antibody-trial-ends",
        "title": "Lilly COVID Antibody Trial Ends",
        "publisher": "Inside INdiana Business"
      },
      {
        "url": "https://www.theindianalawyer.com/articles/lilly-antibody-drug-fails-in-covid-19-study-for-hospitalized-patients",
        "title": "Lilly antibody drug fails in COVID-19 study for hospitalized patients",
        "publisher": "Indiana Lawyer"
      },
      {
        "url": "https://www.bloombergquint.com/coronavirus-outbreak/u-s-run-clinical-trial-of-eli-lilly-antibody-therapy-to-end",
        "title": "U.S. Trial of Lilly Antibody Therapy to End; No Safety Issue",
        "publisher": "BloombergQuint"
      },
      {
        "url": "https://www.nbcbayarea.com/news/coronavirus/lilly-antibody-drug-fails-in-study-of-hospitalized-covid-19-patients/2386756/",
        "title": "Lilly Antibody Drug Fails in Study of Hospitalized COVID-19 Patients",
        "publisher": "NBC Bay Area"
      }
    ]
  },
  {
    "title": "Eli Lilly (LLY) Q3 Earnings and Revenues Miss Estimates - Zacks.com",
    "title_detail": {
      "type": "text/plain",
      "language": null,
      "base": "",
      "value": "Eli Lilly (LLY) Q3 Earnings and Revenues Miss Estimates - Zacks.com"
    },
    "links": [
      {
        "rel": "alternate",
        "type": "text/html",
        "href": "https://www.zacks.com/stock/news/1088134/eli-lilly-lly-q3-earnings-and-revenues-miss-estimates"
      }
    ],
    "link": "https://www.zacks.com/stock/news/1088134/eli-lilly-lly-q3-earnings-and-revenues-miss-estimates",
    "id": "CBMiXmh0dHBzOi8vd3d3LnphY2tzLmNvbS9zdG9jay9uZXdzLzEwODgxMzQvZWxpLWxpbGx5LWxseS1xMy1lYXJuaW5ncy1hbmQtcmV2ZW51ZXMtbWlzcy1lc3RpbWF0ZXPSAWJodHRwczovL3d3dy56YWNrcy5jb20vYW1wL3N0b2NrL25ld3MvMTA4ODEzNC9lbGktbGlsbHktbGx5LXEzLWVhcm5pbmdzLWFuZC1yZXZlbnVlcy1taXNzLWVzdGltYXRlcw",
    "guidislink": false,
    "published": "Tue, 27 Oct 2020 13:48:08 GMT",
    "published_parsed": [
      2020,
      10,
      27,
      13,
      48,
      8,
      1,
      301,
      0
    ],
    "summary": "<a href=\"https://www.zacks.com/stock/news/1088134/eli-lilly-lly-q3-earnings-and-revenues-miss-estimates\" target=\"_blank\">Eli Lilly (LLY) Q3 Earnings and Revenues Miss Estimates</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Zacks.com</font>",
    "summary_detail": {
      "type": "text/html",
      "language": null,
      "base": "",
      "value": "<a href=\"https://www.zacks.com/stock/news/1088134/eli-lilly-lly-q3-earnings-and-revenues-miss-estimates\" target=\"_blank\">Eli Lilly (LLY) Q3 Earnings and Revenues Miss Estimates</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Zacks.com</font>"
    },
    "source": {
      "href": "https://www.zacks.com",
      "title": "Zacks.com"
    },
    "sub_articles": []
  },
  {
    "title": "Care Access Research, Lilly join on mobile COVID-19 trials - OutSourcing-Pharma.com",
    "title_detail": {
      "type": "text/plain",
      "language": null,
      "base": "",
      "value": "Care Access Research, Lilly join on mobile COVID-19 trials - OutSourcing-Pharma.com"
    },
    "links": [
      {
        "rel": "alternate",
        "type": "text/html",
        "href": "https://www.outsourcing-pharma.com/Article/2020/10/27/Care-Access-Research-Lilly-join-on-mobile-COVID-19-trials"
      }
    ],
    "link": "https://www.outsourcing-pharma.com/Article/2020/10/27/Care-Access-Research-Lilly-join-on-mobile-COVID-19-trials",
    "id": "CBMib2h0dHBzOi8vd3d3Lm91dHNvdXJjaW5nLXBoYXJtYS5jb20vQXJ0aWNsZS8yMDIwLzEwLzI3L0NhcmUtQWNjZXNzLVJlc2VhcmNoLUxpbGx5LWpvaW4tb24tbW9iaWxlLUNPVklELTE5LXRyaWFsc9IBAA",
    "guidislink": false,
    "published": "Tue, 27 Oct 2020 13:08:51 GMT",
    "published_parsed": [
      2020,
      10,
      27,
      13,
      8,
      51,
      1,
      301,
      0
    ],
    "summary": "<a href=\"https://www.outsourcing-pharma.com/Article/2020/10/27/Care-Access-Research-Lilly-join-on-mobile-COVID-19-trials\" target=\"_blank\">Care Access Research, Lilly join on mobile COVID-19 trials</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">OutSourcing-Pharma.com</font>",
    "summary_detail": {
      "type": "text/html",
      "language": null,
      "base": "",
      "value": "<a href=\"https://www.outsourcing-pharma.com/Article/2020/10/27/Care-Access-Research-Lilly-join-on-mobile-COVID-19-trials\" target=\"_blank\">Care Access Research, Lilly join on mobile COVID-19 trials</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">OutSourcing-Pharma.com</font>"
    },
    "source": {
      "href": "https://www.outsourcing-pharma.com",
      "title": "OutSourcing-Pharma.com"
    },
    "sub_articles": []
  },
  {
    "title": "AIG, Eli Lilly, Xilinx, Las Vegas Sands: What to Watch When the Stock Market Opens Today - The Wall Street Journal",
    "title_detail": {
      "type": "text/plain",
      "language": null,
      "base": "",
      "value": "AIG, Eli Lilly, Xilinx, Las Vegas Sands: What to Watch When the Stock Market Opens Today - The Wall Street Journal"
    },
    "links": [
      {
        "rel": "alternate",
        "type": "text/html",
        "href": "https://www.wsj.com/articles/aig-eli-lilly-amd-las-vegas-sands-what-to-watch-when-the-stock-market-opens-today-11603797671"
      }
    ],
    "link": "https://www.wsj.com/articles/aig-eli-lilly-amd-las-vegas-sands-what-to-watch-when-the-stock-market-opens-today-11603797671",
    "id": "CAIiEE-tm8kxNwf5Re3fUCcrsvoqGAgEKg8IACoHCAow1tzJATDnyxUwyMrPBg",
    "guidislink": false,
    "published": "Tue, 27 Oct 2020 13:05:32 GMT",
    "published_parsed": [
      2020,
      10,
      27,
      13,
      5,
      32,
      1,
      301,
      0
    ],
    "summary": "<a href=\"https://www.wsj.com/articles/aig-eli-lilly-amd-las-vegas-sands-what-to-watch-when-the-stock-market-opens-today-11603797671\" target=\"_blank\">AIG, Eli Lilly, Xilinx, Las Vegas Sands: What to Watch When the Stock Market Opens Today</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">The Wall Street Journal</font>",
    "summary_detail": {
      "type": "text/html",
      "language": null,
      "base": "",
      "value": "<a href=\"https://www.wsj.com/articles/aig-eli-lilly-amd-las-vegas-sands-what-to-watch-when-the-stock-market-opens-today-11603797671\" target=\"_blank\">AIG, Eli Lilly, Xilinx, Las Vegas Sands: What to Watch When the Stock Market Opens Today</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">The Wall Street Journal</font>"
    },
    "source": {
      "href": "https://www.wsj.com",
      "title": "The Wall Street Journal"
    },
    "sub_articles": []
  },
  {
    "title": "Tumor Infiltrating Lymphocytes Market Growth, Share and Leading Players are Autolus, Bellicum Pharmaceuticals, Inc., Cell Medica., Eli Lilly and Company, Juno Therapeutics, Inc - Illadel Graff Supply",
    "title_detail": {
      "type": "text/plain",
      "language": null,
      "base": "",
      "value": "Tumor Infiltrating Lymphocytes Market Growth, Share and Leading Players are Autolus, Bellicum Pharmaceuticals, Inc., Cell Medica., Eli Lilly and Company, Juno Therapeutics, Inc - Illadel Graff Supply"
    },
    "links": [
      {
        "rel": "alternate",
        "type": "text/html",
        "href": "https://illadelink.com/tumor-infiltrating-lymphocytes-market-growth-share-and-leading-players-are-autolus-bellicum-pharmaceuticals-inc-cell-medica-eli-lilly-and-company-juno-therapeutics-inc/"
      }
    ],
    "link": "https://illadelink.com/tumor-infiltrating-lymphocytes-market-growth-share-and-leading-players-are-autolus-bellicum-pharmaceuticals-inc-cell-medica-eli-lilly-and-company-juno-therapeutics-inc/",
    "id": "CBMivwFodHRwczovL2lsbGFkZWxpbmsuY29tL3R1bW9yLWluZmlsdHJhdGluZy1seW1waG9jeXRlcy1tYXJrZXQtZ3Jvd3RoLXNoYXJlLWFuZC1sZWFkaW5nLXBsYXllcnMtYXJlLWF1dG9sdXMtYmVsbGljdW0tcGhhcm1hY2V1dGljYWxzLWluYy1jZWxsLW1lZGljYS1lbGktbGlsbHktYW5kLWNvbXBhbnktanVuby10aGVyYXBldXRpY3MtaW5jL9IBAA",
    "guidislink": false,
    "published": "Tue, 27 Oct 2020 13:43:50 GMT",
    "published_parsed": [
      2020,
      10,
      27,
      13,
      43,
      50,
      1,
      301,
      0
    ],
    "summary": "<a href=\"https://illadelink.com/tumor-infiltrating-lymphocytes-market-growth-share-and-leading-players-are-autolus-bellicum-pharmaceuticals-inc-cell-medica-eli-lilly-and-company-juno-therapeutics-inc/\" target=\"_blank\">Tumor Infiltrating Lymphocytes Market Growth, Share and Leading Players are Autolus, Bellicum Pharmaceuticals, Inc., Cell Medica., Eli Lilly and Company, Juno Therapeutics, Inc</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Illadel Graff Supply</font>",
    "summary_detail": {
      "type": "text/html",
      "language": null,
      "base": "",
      "value": "<a href=\"https://illadelink.com/tumor-infiltrating-lymphocytes-market-growth-share-and-leading-players-are-autolus-bellicum-pharmaceuticals-inc-cell-medica-eli-lilly-and-company-juno-therapeutics-inc/\" target=\"_blank\">Tumor Infiltrating Lymphocytes Market Growth, Share and Leading Players are Autolus, Bellicum Pharmaceuticals, Inc., Cell Medica., Eli Lilly and Company, Juno Therapeutics, Inc</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Illadel Graff Supply</font>"
    },
    "source": {
      "href": "https://illadelink.com",
      "title": "Illadel Graff Supply"
    },
    "sub_articles": []
  }
]